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More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1
gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the
protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most
often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278
bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179
or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper,
or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar:
47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly
premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to
exon 47. Of all sequence variants determined in our study, !20% represent CrT or GrA transitions within a CpG
dinucleotide, and only six different mutations also occur inNF1 pseudogenes, with five being typical CrT transitions
in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may
account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%)
missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, theGAP-relateddomain
(GRD) and an upstream gene segment comprising exons 11–17. The latter forms a so-called cysteine/serine-rich
domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein
kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those
conserved between human and Drosophila strongly suggest significant functional relevance of this region, with
major roles played by exons 12a and 15 and part of exon 16.
Introduction
Neurofibromatosis type 1 (NF1; also known as “von
Recklinghausen neurofibromatosis” [MIM 162200]) is
a common autosomal dominant disorder affecting ∼1
per 3,000–5,000 people. It is fully penetrant and exhibits
a mutation rate some 10-fold higher than that reported
for most other disease genes. As a consequence, a high
number of sporadic cases (up to 50%) is observed (Upa-
dhyaya and Cooper 1998). NF1 is clinically character-
ized by cutaneous neurofibromas, cafe´-au-lait spots, iris
hamartomas (Lisch nodules), and freckling of axillary
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and inguinal regions. These features are present in 190%
of patients at puberty. Further manifestations, such as
deeply situated and arbitrarily located neurofibromas,
plexiform neurofibromas, optic glioma, macrocephaly,
short stature, learning difficulties, scoliosis, and pseu-
darthrosis, as well as certain malignancies, occur less
frequently among patients with NF1 (Riccardi 1992;
Huson and Hughes 1994; Friedman and Birch 1997).
NF1 is notable for its extreme phenotypic variability,
both within and between families (Riccardi 1992). In
addition to multiple allelism of the NF1 locus, the in-
fluence of modifying genes (Easton et al. 1993) and the
impact of stochastic events (Riccardi et al. 1993) have
been suggested as causes of this variability. So far, none
of these hypotheses has been tested satisfactorily. A com-
prehensive analysis of the mutational spectrum might
help to elucidate the role of different NF1 mutations.
The NF1 gene maps to chromosome 17q11.2 and is
considered to be a tumor-suppressor gene, because loss-
of-function mutations have been associated with the oc-
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Table1
Pre-Amplification PCR Primers and Conditions for Nested PCRs in the TGGE
Approach
Exon
Primer Sequencesa
(5′r3′)
Fragment Size
(bp) Ta (C)
b
1 CAGACCCTCTCCTTGCCTCTT 433 66
GGATGGAGGGTCGGAGGCTG
7 TAATTTGCTATAATATTAGCTAC 323 54
ATAATACTTATGCTAGAAAATTC
9 AGAAATAATCTGCTTTTTTTTTTC 1,341 59
TACAATTTAACTCAGTGATACTC
14 - 18 CTCTGCCTAAGTTGTAGATAGTGAAG 3,595 53r51
TTAGGGAAATTTGAGAAGAGATGT
23–1 TTTGTATCATTCATTTTGTGTGTA 282 56
AAAAACAGCGGTTCTATGTGAAAAG
23–2 CTTAATGTCTGTATAAGAGTCTC 268 56
ACTTTAGATTAATAATGGTAATCTC
23a AGCCAGAAATAGTAGACATGATTGGGT 446 56
CTATTTTGTGCCAGAATTAGTAGA
24 TTGAACTCTTTGTTTTCATGTCTT 266 58
GGAATTTAAGATAGCTAGATTATC
32–36 TTGATTAGGCTGTTCCAATGAATA 1,936 53r50
TCATAAATATTTGGGAGAAGTGAGG
a Primers for the amplification of exons 1, 23-1, 23-2, 23a, and 24 are from
Purandare et al. (1995).
b Two different annealing temperatures (Ta) connected with an arrow indicate a
touch-down PCR protocol with the first 8 cycles being performed at the higher
temperature.
currence of benign and malignant tumors in neural-
crest–derived tissues (Legius et al. 1993; Colman et al.
1995; Serra et al. 1997) as well as myeloid malignancies
(Shannon et al. 1994). The NF1 gene was cloned in
1990 (White and O’Connell 1991). It spans over 350
kb of genomic DNA comprising 60 exons. The open-
reading frame codes for 2,867 amino acids, including
three alternatively spliced exons. The most common
transcript codes for a polypeptide of 2,818 amino acids
called neurofibromin (Marchuk et al. 1991; Danglot et
al. 1995; Li et al. 1995). A central region of about 360
amino acids shows significant homology to the mam-
malian GTPase-activating protein (GAP) (Xu et al.
1990). This region, the NF1 GAP-related domain
(GRD), is encoded by the exons 20–27a and has been
found to interact with p21ras (Martin et al. 1990). As a
result of this interaction, GTP•Ras levels may be ele-
vated in human NF1 peripheral nerve tumors, in which
neurofibromin is usually found to be totally absent or,
at least, dramatically reduced (Guha et al. 1996). Com-
mensurate with its pivotal functional significance, sev-
eral missense mutations were identified in the GRD (Li
et al. 1992; Upadhyaya et al. 1997; Kim and Tamanoi
1998; Klose et al. 1998a).
In general, mutation analysis of the NF1 gene has
turned out to be a major challenge, for several reasons.
The large size of the gene under investigation and the
diversity of the underlying pathological lesions (Korf
1998; Upadhyaya and Cooper 1998) make analysis
problematic. In addition, the presence in the genome of
several unprocessedNF1 pseudogenes severely hampers
PCR approaches to the analysis of genomic DNA sam-
ples, because of coamplification of homologous se-
quences of theNF1-like loci at other chromosomes (Pur-
andare et al. 1995; Re´gnier et al. 1997). Most of the
NF1 mutations are point mutations or other small le-
sions leading to premature termination codons (PTCs)
(Upadhyaya and Cooper 1998). Hence, the application
of the protein truncation test (PTT) was thought to sub-
stantially accelerate the rate of identification of NF1
mutations. In an initial study, mutations were identified
in 14 (67%) of 21 individuals (Heim et al. 1995). Before
PTT was introduced, the best results had been obtained
by using chemical mismatch cleavage analysis. In a
study covering 70% of the coding sequence, seven mu-
tations were found in 25 patients (28%) (Purandare et
al. 1994). In a more recent study, by using a combined
heteroduplex/SSCP approach, researchers identified
only 13 disease-causing mutations in 67 unrelated NF1
patients (a 19% detection rate), even though as many
as 45 exons were tested (Abernathy et al. 1997). Most
other analyses focused on one or a few arbitrarily se-
lected exons but sometimes were performed in very
large cohorts of NF1 patients (e.g., Maynard et al.
1997).
Together with multiple reports of isolated mutations,
792
Table 2
TGGE-PCR Primers and Conditions
Exona Primer Sequences (5′r3′)b
Fragment Size
(bp) Ta (C)
c
TGGE Conditionsd
(gradient, running time # voltage)
1 (nested) TATTCTCTCCGTCGCCCCCC 137 59 30–60C, 2 h # 300 V
p-AACCCCCACTCCGCTCCC
2 TAAGGATAAGCTGTTAACGTG 221 55 25–55C, 3 h # 300 V
p-AATTCCCCAAAACACAGTA
3 p-AATGGTAGCAGAAAGTGAAAC 175 58 35–60C, 1 h 30 min # 300 V
AATTCACAAAGCCTGCCTAC
4a TTGTTCTGTGTGTGTGTTTG 316 56 32–53C, 2 h 30 min # 300 V
p-A-ACTTCAGTAGTCCCATGTGG (35–70C, 5 h # 300 V)e
4b CTGTCCCCTAATACTTAATT 209 52 29–52C, 3 h 15 min # 300 V
p-A-ATACTAGTTTTTGACCCAGT
4c p-AA-GCTCTGAGTTGTATTTGTGT 190 51 27–53C, 3 h 15 min # 300 V
ACAACAGCAAATTTTACATC
5 GAAGGAAGTTAGAAGTTTGTG 213 54 30–60C, 1 h 30 min # 300 V
p-AA-CACAAGTAGGCATTTAAAAGA
6 p-A-AATGCCAGGGATTTTGT 247 47 35–60C, 1 h 30 min # 300 V
p-AA-TAGATATAATGGAAATAATTTTG
7 (nested) GAAACTTCATATATTATCTTA 254 52 30–60C, 2 h 30 min # 300 V
p-AA-CTTAAAGTTTGTAGTAGA
8 p-AA-TTGTGTGGGTAATGTGTTGA 248 52 30–60C, 2 h 15 min # 300 V
AAATATAGTTAGATAAAAACCAATG
9 (nested) p-AATCTGCTTTTTTTTTTCTTT 136 51 30–60C, 1 h 30 min # 300 V
p-AA-TTTAGTAATTTAGCAATAC
AATCTGCTTTTTTTTTTCTTT 136 51 30–60C, 2 h # 300 V
p-AA-TTTAGTAATTTAGCAATAC
9br p-AATTGTGAAATATTTTTGTCTAC 102 52 32–62C, 55 min # 300 V
CTTGGAACCCAGAAAGGAA
10a p-AATTTTGTACTTTTTCTTCC 217 53 30–60C, 2 h 10 min # 300 V
AATAGAAAGGAGGTGAGA
10b p-A-ATTATCCTGAGTCTTACGTC 229 51 30–70C, 50 min # 300 V
p-AA-TAACTTAGTGTGATAATTT
10c ATTTTTTTTAATTGAAGTTTC 186 50 30–60C, 2 h 30 min # 300 V
p-AA-TTCCTTCAAGAACATGGAA
11 AAGTACTCCAGTGTTATGTTTAC 205 52 20–45C, 3 h # 300 V
p-A-ACAAAATAAAATTTAAAAGTTGAA
12a CTAAGCTTCTCTAAACTTGTATTCA 297 62 25–55C, 3 h # 300 V
p-AATCTCTCACCATTACCATTCC
12b GTGTTTATTCCTCTTGGTTGTC 274 59 25–55C, 3 h 30 min # 300 V
p-AA-ATTCAGAAAACAAACAGAGCAC
13 CCCAAGTTGCAAATATATGTC 277 60 35–65C, 4 h 30 min # 300 V
p-A-ATTGCTGACAGAGGCAAACTC
CTCTTGCCCAACTATAACAC 89 58 35–65C, 2 h 30 min # 300 V
p-A-AGTAAAAAAAACCACTATTCAC
14 (nested) p-AA-CCTACTCCTTTTGGGTGGAGCTTA 191 55 31–61C, 2 h 40 min # 400 V
GGGGTGTTTCTGTTGCTA
15 (nested) p-AATATACATCAAGTTTGAAACTT 208 55 28–60C, 2 h 10 min # 400 V
AGTTAACAGACAAAAGTCAACTT
16 (nested) p-AATGTTGGATAAAGCATAATTT 330 55 31–61C, 2 h 40 min # 400 V
p-AA-CGTTTCCCTCTGAAGACA
p-AAGGGTTCTATGATTTCATGAT 275 55 31–61C, 2 h 40 min # 400 V
p-AA-CACTCTATTCATAGAGAAAGGTG
17 (nested) p-AA-TCATCTCTCTAGGGGGTCT 240 55 31–61C, 2 h 40 min # 400 V
ATGTTTCTGCTACATTTCAGTA
GATGGCAAATCATTAATGTAT 204 55 28–60C, 2 h 10 min # 400 V
p-AATGTTTCTGCTACATTTCAG
18 (nested) p-AA-TGATAATTTTTTTATTGTTTCTATG 230 55 31–61C, 2 h 40 min # 400 V
TGTACTTCATTGGACATATTAAGATTTACA
p-AA-TATTTAGAATGCCTTCTCTTTTG 222 55 28–60C, 2 h 10 min # 400 V
TACAAGACCCTACATTGCTC
(continued)
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Table 2 Continued
Exona Primer Sequences (5′r3′)b
Fragment Size
(bp) Ta (C)
c
TGGE Conditionsd
(gradient, running time # voltage)
19a GTGTGTGTGTGGCTTCAAAA 192 60 30–55C, 3 h 30 min # 300 V
p-AACTCTCACAGTAAAACCCACTAA
19b TTTTTTTTCAGAGATTTGGACCA 174 58 30–55C, 3 h 3 min # 300 V
p-AA-GCTTTATTTGCTTTTTGCTTTA
20 p-A-ATACGGCCTTCACTATGTAAAGGT 276 58 30–60C, 3 h # 300 V
GCCAGTTCTCTAGGTTTTGT
21 p-AA-GCATGTAAGAGAAGCAAAAATTA 328 55 35–60C, 3 h # 300 V
CTATGTGCCAGGCACTTTTC
22 TCTTTAGCTTCCTACCTAAGAA 262 59 30–55C, 4 h # 300 V
p-A-ACACACATACACACAAAATGAA
23-1 (nested) p-AAGGTAAAATATATGGAGCAG 191 63 25–55C, 3 h # 300 V
AAAACAGCGGTTCTATGTG
23-2 (nested) p-AAGTGTTAGGATTTTATTTTTATTTTTT 93 59 35–65C, 1 h 30 min # 300 V
TTTTCAGTCATCTGAAGGAGG
GTTAGAACCATCAGAGAGC 159 59 33–63C, 3 h 30 min # 300 V
p-AA-GTAATCTCTAACTGTAAGCAT
23a (nested) GCTGTATGTAGTCGGTGCT 78 58 33–63C, 1 h 30 min # 300 V
p-AA-TTTATTCAGTAGGGAGTGGCA
TGCTCATCTCTGTTCTGTA 113 55r53 33–63C, 1 h 15 min # 300 V
p-AACAGCTAATAAAAAGTTCTCC
24 (nested) AACTCCTTGTTTTTAGGTGG 171 56 37–67C, 2 h 30 min # 400 V
p-AA-GACATTAACTTCAAGCCC
ACCTTTGAACTCTTTGTTTTCAT 230 52 37–67C, 2 h 30 min # 400 V
p-AA-GACATTAACTTCAAGCCC
p-AA-TTCAAACCTTATACTCAATTC 238 48 30–60C, 2 h 10 min # 400 V
AAGGGGAATTTAAGATAGCTAG
25 p-AACCCTGTTTTATTGTGTAG 138 62 30–60C, 5 h 20 min # 300 V
GTAAGTGGCAAGAAAATTAC
26 TGAAAATTCTAATGACTTTGC 212 64 30–60C, 2 h 40 min # 300 V
p-A-AGTGTTCACTATCCCCATGAC
27a TGTGTAGTGCTAAATGTG 263 54 30–60C, 2 h 30 min # 300 V
p-AA-GCAAACTCTCCTTCTCAAC
27b p-AA-CTACTCAGTAGACAACAT 195 55 25–55C, 3 h # 300 V
GTTAAGAGACCCAAAACATAG
28 TCTTTGTCTTTTTTGTCATTTTCC 509 60 SSCPd
AGTCAAGAAAAGCAATGAATCGT
29 TCACCCCGTCACCACCACTTT 411 60 SSCPd
GCAACAACCCCAAATCAAACTGA
30 p-AA-GGAACTATAAGGAAAAATACG 181 57 25–55C, 3 h 30 min # 300 V
ACTAATAGAGACAATAAAGAGGG
GCCAGTTACTAGAGACAT 182 50 25–55C, 3 h 30 min # 300 V
p-AATAATTGTTAGTATTAAAGAAAA
31 p-A-ATTGACCATCACATGCTAATAG 260 62 30–55C, 2 h 30 min # 300 V
CTAGATAAATATTTGAGCAAACTC
32 (nested) p-AA-TGATTAGGCTGTTCCAATGAATA 156 48 30–64C, 2 h 30 min # 400 V
p-AA-TGATCCCAAGCCACCTGTT
p-AA-CTTGATGTTGTACTAGACAGTT 156 48 30–64C, 2 h 30 min # 400 V
p-AA-TACAGAAGGCAAAAGAAAAGTGAT
33 (nested) p-AATTAAACTGAACTTTTTTGTGCTA 204 48 30–64C, 2 h 30 min # 400 V
p-AA-GAAGGACAGCATCAGCATGTA
p-A-ATGTGGGATGATATTGCTATTTTA 202 48 30–64C, 2 h 30 min # 400 V
p-AATGAAGCTGTGAACAAGTACA
p-A-ATGGACTGGTCATTAATATCATT 114 48 30–64C, 2 h 30 min # 400 V
p-AA-GAAGTAAAATGGAGAAAGGAACT
34 (nested) p-A-ATGGAACTTTAGAAATTAAAAAGTA 187 48 30–64C, 2 h 30 min # 400 V
p-AA-CCCGGTAACTGGAACGGAA
p-AA-CAAAGTCAAGTCAGCTGCTGT 179 48 30–64C, 2 h 30 min # 400 V
p-AAGATTTTAACTTAGTTTCTTATCA
(continued)
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Table 2 Continued
Exona Primer Sequences (5′r3′)b
Fragment Size
(bp) Ta (C)
c
TGGE Conditionsd
(gradient, running time # voltage)
35 (nested) p-A-ATCATAATAAACATTATTTAAACAGTT 168 48 30–60C, 2 h 30 min # 400 V
p-AA-TTTACAACTTATATTTAATTTAGGA
36 (nested) p-AAGGTTTTTATAAGTTCTGTGGAT 189 48 30–60C, 2 h 30 min # 400 V
p-AA-CATAAATATTTGGGAGAAGTGAGG
37 TCCGAGATTCAGTTTAGGAGT 203 51 25–55C, 3 h # 300 V
p-AATGCACTCATTTTCTATACAGTA
38 p-AA-TTGAAAGAGACTATGTCATGAT 235 62 30–60C, 2 h # 300 V
p-AA-GAGTAATCTAGGAACCTCAAG
39 CCTTTAAAGAAAGCTACTG 215 48 30–60C, 2 h # 300 V
p-A-ATAAAAATATTCTAAATAAGGC
40 p-A-AGATGCTTGTTCAAAAAATTA 241 52 30–60C, 4 h # 300 V
TATATATAGATGTAGCAAGAT
AAGATGCTTGTTCAAAAAATTA 241 52 30–60C, 4 h # 300 V
p-AA-TATATATAGATGTAGCAAGAT
41 GAGACTGTAAGAAGTTCATC 268 50 25–49C, 2 h 30 min # 300 V
p-AATTGAAACTTGATTATGATTA
42 p-AA-TAATTGATTTTTCTCTATTG 230 52 30–60C, 4 h 30 min # 300 V
AATAATAAAAAAAATCTACATAAT
43 p-A-ATGTCCAAACATTTTCTTTTT 251 53 30–60C, 3 h 30 min # 300 V
CCACCTTATTTTCAATGATC
44 p-AACATTGAAATAGTTAGGTGAA 253 52 35–65C, 2 h 45 min # 300 V
TAGACTGGAATAAAAATTTG
45 p-AA-CCACAAAGTAAAAATGTTGT 179 49 30–58C, 2 h 15 min # 300 V
AAGGTGAATTAAAATCAAAA
46 p-A-ATTTTCATTTAATTTTCCTCT 246 48 30–55C, 1 h 50 min # 300 V
ATGTTAGCAAGTTCATCAAC
47 p-A-ATTTAATTTCTGTTACAATT 143 44 26–52C, 3 h # 300 V
CAAAAGTTAGAGAAAAATAT
48 p-AACTAAAATAATTTCCTATTTTCC 294 58 35–55C, 3 h 45 min # 300 V
p-AA-GTCTTATATTGTTGCTCAAAGT
48a p-AATCTTATGAACATCACTTACTT 134 54 35–55C, 2 h # 300 V
CGTGCAAAGATGATGAAAA
49 CCTGGAAGGAAAAGAAGA 216 56 35–60C, 4 h # 300 V
p-AA-GATTTTAAAAAAGAAAGCAA
a For TGGE, exons were amplified directly from genomic DNA or, as indicated, from a preamplified PCR product (see table
1) using nested TGGE-PCR primers.
b Psoralen modification is indicated by “p-”; note that psoralen is followed by two adenosine residues irrespective of the
target sequence.
c Ta is the annealing temperature for the primers during PCR.
d The exons 28 and 29 were investigated by single-strand conformation polymorphism (SSCP) analysis in lieu of TGGE (see
Peters et al. [1999b]).
e A second TGGE analysis of exon 4a was performed after digesting the PCR product with Tru 9 I.
most of these data have been submitted to the NF1
Genetic Analysis Consortium. The consortium was or-
ganized in the autumn of 1992 to facilitate mutation
detection in the NF1 gene and to pool mutation data
into a common database for better interpretation of the
growing body of information. By November 1997 a
total of 240 mutations, including 173 minor lesions
(72%) had been reported to the consortium (Korf
1998). The mutational spectrum obtained from these
data, however, suffers from a strong bias towards more
thoroughly investigated regions of the NF1 gene. To
overcome this drawback, we launched a mutation-
screening project in Germany aimed at the complete
analysis of the entire NF1 gene in a large cohort of
unrelated NF1 patients. According to the preferences of
the participating centers, PTT, temperature-gradient gel
electrophoresis (TGGE) analysis (Riesner et al. 1989;
Wartell et al. 1990), and direct genomic sequencing
(DGS) of all individual exons were used for our analysis.
Materials and Methods
Patient Samples
The study was approved by the ethics committee of
the Charite´ University Hospital. NF1 diagnostic criteria
Table 3
DGS-PCR Primers and Conditions
Exon
Primer Sequencesa
(5′r3′)
Fragment Size
(bp) Ta(C)
b
1 CACAGACCCTCTCCTTGCCTCTTC 233 66
TACCTCCCCTCACCTACTCTGTCC
2 TCTGTGGTTGATGCAGTTTTCC 371 62
TATATCCAAAGTCCACAGAAAATC
3 TGGTAGCAGAAAGTGAAACTA 224 56
ATAGGACTGTCTCTGGTCCATC
4a GTTTGAAAATTTTCATAATAGAAAATG 419 60
GGAGGTCAAAGCTGCTGTGAG
4b GAACTCCTGGCCTCAAGTGGTC 349 62
ATGTCATTATAAAATCCAGTTTGGTG
4c GCAAAAGTAATACGTAAATGGAAAG 904 62
TGATGTACCCAAGCAACAAAGAC
5 (amplification as for 4c) 904 62
[TGACTTGAGTGATAGTTTCACAT]
6 CATGTTTATCTTTTAAAAATGTTGCC C333 62
TTGAGTAAAATAAACTGCTTCACAT
7 ATTTGCTATAATATTAGCTACATCTGG 387 62
AAAGCAAGTCCTATGAACTTATCAAC
8 GGATTTTACTGCCATTTGTGTG 237 60
TAACAGCATCAGTAAATATAGTTAGATA
9 CTTAGTGTTTTTTTTTTAQAACTTTCTA 224 54
ATTTTTTTAGTAATTTAGCAATACC
9br GCTTAAAATTTGTATACAATAAAC 193 62
ATGCATGAAGCACCACTCCAGG
10a GATAAAACTTAAAAQCTACAGTGATAAACAG 270 62
GCAATAGAAAGGAGGTGAGATTC
10b CTTTAAAGTGATAGCTATTACCTGAGTC 288 60
CTAAAAAGTATCCTCCAGGTCTTG
10c AAACTTGGTACCCTTTAGCAGTC 348 60
GTATAGACATAAACATACCATTTC
11 GTACTCCAGTGTTATGTTTACC 268 64
AAAACCTTTGGAAGTGTAAGTTTTAC
12a TGTATTCATTATGGGAGAATGCC 267 64
ATTACCATTCCAAATATTCTTCCA
12b AAGTTGGGGCATAGAGATTGAGAG 363 66
GATGAAATTTACCAAATTTCATTCAG
13 CACAGTTTATTGCATTGTTAG 376 60
GCCATGTGCTTTGAGGCAG
14 TCCTACTCCTTTTGGGTGGAG 511 54
TTAACAGATAAAAGTCAACTTTACAG
15 (amplification as for 14) 511 54
[TGTGATCAGGAATAGCTTTTG]
16 TGGATAAAGCATAATTTGTCAAGT 628 60
GGAAATTTTTAAAAACTGTGAGTACC
TCAGTGAACGTAAGGGTTCTATG
17 GGTGCACTTACTCTGTGTGTTTAG 808 64
GGGAAATTTGAGAAGAGATGTAGAG
18 (amplification as for 17) 808 64
[GCCATTCTTTACTGCACACAAAC]
19a GCCATTCTTTACTGCACACAAAC 985 60
AAACAAAAGTTTGACATCTCAAAAG
[TCATGTCACTTAGGTTATCTGG]
19b ATTTAAGGGGAAGTGAAAGAAC 242 56
TGGTGGGGGGCTTTATTTGC
20 CTATATCAGGTAAAATCATGTCCAAC 758 62
GATTTGCTATGTGCCAGGGAC
21 (amplification as for 20) 758 62
[GGTCTCATGCACTCCATAGGTG]
(continued)
Table 3 Continued
Exon
Primer Sequencesa
(5′r3′)
Fragment Size
(bp) Ta(C)
b
22 GCTACTCTTTAGCTTCCTACCTAAG 518 60
AAAAACAGCGGTTCTATGTGAAAAG
[CCTTAAAAGAAGACAATCAGCC]
23-1 (amplification as for 22) 518 60
[TTTGTATCATTCATTTTGTGTGTA]
23-2 GGCTTAATGTCTGTATAAGAGTCTC 270 60
ACTTTAGATTAATAATGGTAATCTC
23a AGCCAGAAATAGTATACATGATTGGGT 448 60
CTATTTTCTGCCAGAATTAGTAGA
24 AATAAGACAAGCTATGTCTTGACCTAG 1023 60
GAGTTTTTATGCAAAGTTTGACC
25 (amplification as for 24) 1023 60
[TTAAGTACTAGCAGAAATTATATCAATGAG]
26 GCTTTGTCTAATGTCAAGTCAC 339 62
TTAAACGGAGAGTGTTCACTATC
27a ATGGTCCTGAGGTCTTTTTG 360 66
CTAACAAGTGGCCTGGTGGC
27b TTGCTTTTAAAATATTTTTTCATTTTAG 329 56
ACCTCCTGTTAAGTCAACTGGG
28 TTTAAAAAATGAATCCAGACTTTGAAG 696 62
GCCTTACGTGACATTTTATACACCAC
[TGCAAAGCCATATGAAATTGTAGTG]
29 GTTGGTTTCTGGAGCCTTTTAG 489 60
AAATGGTCTCATTTTAAAAGCAAC
30 TTAAGGGGTATTTTGGTTTTACTG 530 62
AGGATACCACAGATATAAAATCAGAAG
31 TTTTTTCCCCGAATTCTTTATG 429 56
GTGAGTGTCTACATGCTTTCTGAAG
32 TGACAGGCCTGTAAATAAAATCTAG 885 58
TTTTGGTAATATTTCATGTCATTACTG
33 (amplification as for 32) 885 58
[TTTTGGTAATATTTCATGTCATTACTG]
34 GTTTGATTTAGGGAACATGAT 794 62
CTGCAATTAAAAGATCCACAGAAC
35 (amplification as for 34) 794 62
[CTGTGTTATTGGTAACAGGTCAC]
36 GCTGGACCAGTGGACAGAAC 392 62
TCATTGACCTCAAATTTAAACGTC
37 ATAGCATGAGAAATCATTCTAG 439 62
CAAGCGCTTGAGAACATACTATC
38 GTTCTCAGTCCAGCTAACAGTGTC 530 60
ATGTAAAAAATATGCATTCAAGTTTAC
39 TGCTTGACTGTCTTGCACCAG 511 66
CAAGTGATCCTCCTGCCTCAG
40 ATTCACATATGCATGTTTTACCTTC 556 64
GATAACAGAGAGCCACTGTAGTGTC
41 TGCTTATTAAATCTCTCTGTATATTTC 436 64
TTTCACTTACTCTTCCTAGGCCATC
42 CCTAGGGATACACCAAGAGTTTG 428 62
ACATGGAAAATTTTGATAATCCTG
43 CTCAGTGAAAGCTTAAACACTTTATG 1144 60
AAAGCTAAAATCACTATCACAATATCTC
44 (amplification as for 43) 1144 60
[CGAATAGTAATTCTCTATGATGTTTATG]
45 (amplification as for 43) 1144 60
[CCCTCAAATTTTTATTCCAGTC]
46 ATTGTAGAAAATTTGGAAAATGAAG 856 58
ATGAGAAACTTTTTATAAAAGTAACATATG
(continued)
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Table 3 Continued
Exon
Primer Sequencesa
(5′r3′)
Fragment Size
(bp) Ta(C)
b
47 (amplification as for 46) 856 58
[TTTAGTTGCTTTGACACTCATTC]
48 AAGGAAGAAAAATAGTAAATTAAGTCC 421 60
AAGGAGCAAAATTTGCTATAAAC
48a ATTCAATAATTAAAACCAGATTCC 327 64
GGTGGCTTTACAAGTTCCTAAAG
49 TTCCTAGAATGTGTCCCCGTTG 931 62
ATATATGTGGTCGCACTTATTTTCCTG
[CCATGTTGTAATGCTGCACTTC]
a Primers used for sequencing but not for amplification are shown in square
brackets.
b Ta is the annealing temperature for the primers during PCR.
(Gutmann et al. 1997) were used to identify 521 un-
related patients with NF1, all of whom were of German
or Turkish descent. Once informed consent was ob-
tained, DNA from peripheral blood was obtained from
each patient, applying one of several standard proce-
dures. RNAwas also obtained from some patients, either
from fresh blood or from cell cultures (i.e., fibroblast-
like cells or Epstein-Barr virus–transformed lympho-
cytes) by using the RNeasy total RNA purification kit
(Qiagen). The SuperScript preamplification system (BRL
Gibco) was used to prepare cDNA from the RNA sam-
ples. The cDNA reaction was performed in a 20-ml re-
action volume containing 2–3 mg total RNA, 1.5 mg
random hexamers (BRL Gibco), 0.5 mg single-stranded
binding protein (Promega), 20 units RNAsin (Promega),
4 mM each dNTP, and 300 U Superscript II reverse
transcriptase (RT) (BRL Gibco). cDNA was stored at -
20C.
Analysis of NF1 Gene Expression
Allele-specific expression level studies were performed
by RT-PCR reactions by using the following primer pair
to amplify the polymorphic exon 5 (Hoffmeyer and As-
sum 1994) from cDNA: 5′-TAGTCGCATTTCTAC-
CAGGTTA-3′ (sense primer) and 5′-GAGAATGGCT-
TACTTGGATTAAA-3′ (antisense primer). Thirty PCR
cycles of 1 min at 92C, 1 min at 54C, and 1 min at
72C were used. After RsaI restriction, the fragments
were analyzed by agarose gel electrophoresis and ethi-
dium bromide staining. Subsequently, the band inten-
sities were measured densitometrically by using a charge-
coupled-device camera and the ImageQuant software
package distributed with the Phosphoimager from Mo-
lecular Dynamics.
PTT
RT-PCR.—Hot-start PCR reactions to amplify each of
the five overlapping segments required that 2.5–3 ml
cDNA be added to a lower-phase PCR mixture con-
taining 1# PCR buffer (50 mM KCl, 10 mM Tris, pH
8.3, and 2 mM MgCl2), 0.8 mM each dNTP, and 10
pmol each primer (primer sequences were as described
elsewhere (Heim et al. 1995) in a total volume of 40 ml.
A wax gem (Perkin Elmer) was added to each tube.
Reaction mixtures were heated to 80C for 5 min, fol-
lowed by cooling to room temperature. A 10-ml upper-
phase mixture containing 1# PCR buffer, 0.25 mg sin-
gle-stranded binding protein, and 2.5 units Taq poly-
merase (Pharmacia) was layered onto the solidified wax.
Reactions were performed in a Cetus model 9600 ther-
mal cycler (PE Biosystems), under the following condi-
tions: 95C for 1 min; 40 cycles of 95C for 30 s, 61.5C
for 30 s, and 72C for 90 s; and 72C for 10 min. The
PCR products were analyzed by agarose gel electropho-
resis. Apparent splice defects, for example, exon skip-
ping events, were verified by cDNA sequencing by using
radioactive labeling and the Thermo Sequenase kit
(Amersham Life Science). Subsequently, the presumably
mutated exons or exon/intron boundaries were se-
quenced from the patients’ genomic DNA samples.
In vitro transcription/translation and analysis of the
peptides.—For each in vitro transcription/translation re-
action, 4–9.5 ml PCR product (volume depends on the
quality of the PCR product) and 0.5 ml 35S-methionine
(specific activity: 11000 Ci/mmol; Amersham) were
added to the commercially available TNTTM Coupled
Reticulocyte Lysate System (Promega). Reactions were
performed under conditions recommended by the man-
ufacturer, with 1 exception: for all components, only a
one-half volume was added to the PTT reaction (e.g.,
12.5 ml TNT Rabbit Reticulocyte Lysate). After incu-
bation of the complete reaction for 1.5 h at 30C, 5 ml
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of the reaction was added to 5 ml loading buffer (10%
glycerol, 5% 2-mercaptoethanol, 2% SDS, and 0.1%
bromphenol blue), and was heated for 5min, then placed
on ice. Samples were subjected to electrophoresis in a
14% SDS-polyacrylamide gel for 1.5–2 h at 40 mA
(Rainbow 14C methylated protein (Amersham) was used
as a protein-weight marker). The gel was fixed in a so-
lution of 40% methanol and 10% acetic acid and dried
for 1.5 h at 80C in a gel dryer. The synthesized poly-
peptides were visualized by means of a Phosphoimager
(Molecular Dynamics) after the gel had been exposed
overnight to a special film slide (Molecular Dynamics).
On the basis of the determined fragment size, the po-
sitions of the mutations causing shortened polypeptides
in the PTT were predicted and the presumably affected
exons were sequenced from the patient DNA samples.
Either the Thermo Sequenase kit (Amersham Life Sci-
ence) and radioactive labeling were used for DNA se-
quencing or samples were analyzed on an ABI 377
PRISM DNA Sequencer by using the Big Dye terminator
chemistry (see below).
TGGE
For TGGE analysis, the individual NF1 exons were
usually amplified directly from genomic DNA. For sev-
eral exons, however, preamplification of a larger ge-
nomic fragment was necessary (see table 1) to improve
specificity—that is, either to avoid coamplification of
NF1 pseudogenes or simply to relieve constraints of
TGGE primer design. Final TGGE primers were chosen
by using the programs MELT87 and SQHTX (Lerman
and Silverstein 1987), which allow prediction of the im-
pact of mutations on the melting behavior of the PCR
products. Sequences containing two or more melting do-
mains were split into several overlapping fragments.One
or both oligonucleotides of each primer pair were 5′-
modified with psoralen (table 2). Using two psoralen-
modified primers in one reaction results in bipolar
clamping of the fragments that may improve the sensi-
tivity of mutation detection (Gille et al. 1998). For PCR,
some 100 ng of genomic DNA (for the nested PCRs, 50
ng PCR product is required) were added to 25 ml stan-
dard Perkin Elmer PCR buffer containing 1.5 mM
MgCl2, 200 mM each dNTP, 0.2 mM each primer, and
0.5 U Taq polymerase. All reactions were performed on
a Perkin Elmer thermocycler (model T1), under the fol-
lowing conditions: 95C for 3 min; 35 amplification cy-
cles of 95C for 30 s, specific annealing temperature Ta
(seetable 2) for 30 s, and 72C for 50 s (final extension
for 10 min). A commercially available apparatus was
used for TGGE (Diagen GmbH, Germany). Prior to elec-
trophoresis, the PCR products were placed directly un-
der a portable UV light source (365 nm) for 15 min to
permit cross-linking of the psoralen moiety to the thy-
mine residues of the opposite DNA strand. For exons
2–49, TGGE was done on an 8% polyacrylamide gel
with 8M urea in 3–N-morpholino–propanesulfonic acid
(MOPS) buffer. For exon 1, an 8% polyacrylamide gel
with 7 M urea and 35% formamide in MOPS buffer
was used. The individual running conditions for each
exon are given intable 2. Silver staining was used for
visualization of bands. Samples that showed altered mo-
bility patterns were subjected to DNA sequencing, as
described below. Alternatively, radioactive labeling and
the Thermo Sequenase kit (Amersham Life Science) were
used for sequencing.
DGS
For DGS-PCR, samples were cycled with a first acti-
vating step for HotStarTaq (Qiagen) at 95C for 3 min.
Primer sequences, fragment sizes, and annealing tem-
peratures are given in table 3. Each cycle consisted of a
denaturation step at 95C for 90 s, annealing for 40 s
(48C to 65C, see table 3) and an extension step for 1
min at 72C. 35 cycles were performed in a 20-ml re-
action volume on a 9700 thermal cycler (PE Applied
Biosystems). PCR products were purified by using the
PCR Product Purification Kit (Qiagen) according to the
manufacturer’s protocol. Cycle sequencing was per-
formed in a 5-ml volume at 60C with 25 cycles. Se-
quencing products were purified on Sephadex G-50-80
columns (Sigma) and analyzed on an ABI 377 automated
DNA sequencer (PE Applied Biosystems).
Results
Synopsis of Mutation Screening
We analyzed 521 unrelated patients with NF1 by
means of PTT, TGGE, or DGS for mutations in the
whole coding sequence and the splice sites of the NF1
gene. Twenty patients were included in both the PTT
and the TGGE screening program. In total, we identified
301 sequence changes (table 4), 278 of which were con-
sidered pathogenic. The detection rates for the different
methods were 40/85 (47.1%) for PTT, 65/121 (53.7%)
for TGGE, and 184/335 (54.9%) for DGS. The muta-
tions of 11 patients were identified independently by
PTT as well as by TGGE. Among the 278 mutations
identified, we observed 84 (30.2%) nonsense mutations
and 140 (50.4%) frameshift mutations, comprising 78
deletions and 32 insertions of one or a few base pairs,
as well as 30 out-of-frame exon skipping events. Thus,
as many as 224 (80.6%) mutations caused, directly or
indirectly, a premature termination codon (PTC). An-
other 25 (9.0%) of the mutations caused in-frame exon
skipping. Furthermore, 28 (10.1%) missense mutations
and one initiation codon mutation were also observed.
Most mutations were found only once in any one pa-
Table 4
Summary of NF1 Mutations and Sequence Variants Detected with PTT, TGGE, and DGS
Patienta Location Sequence Changeb
CpGc
(CpNpG) RNA Leveld Protein Leveld,c Mutation Type
Reference;
NF1 Mutation
Database No.
2318 Exon 1 T2C M1T; initiation at
M68, M102 or
M108 (?)
(Missense); faulty initiation This report
34 Exon 1 G26A No W9X Nonsense This report
650 Exon 1 G55T E19X Nonsense This report
1852 Exon 2 C147G Y49X Nonsense This report
348 Exon 2 C168T Yes S56S Silent This report
2732 Exon 2 C168T Yes S56S Silent This report
2938 Intron 2 2041GrT Skip of exon 2 (?) In frame; 48 aa Splice site This report
710 Intron 2 2042TrG Skip of exon 2 (?) In frame; 48 aa Splice site This report
1972 Intron 2 2051GrA No Skip of exon 3 (?) In frame; 28 aa Splice site This report
119 Exon 3 220delG aa 74; PTC 84 1-bp deletion This report
214 Exon 3 227insA aa 76; PTC 106 1-bp insertion This report
2170 Exon 4a 426delATTTT aa 142144; PTC
153
5-bp deletion This report
2253 Exon 4b T482A L161X Nonsense This report
420 Exon 4b 496delGT aa 166; PTC 172 2-bp deletion Toliat et al. (1999); 844
461 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion This report
1062 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion This report
110 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion Toliat et al. (1999); 843
U-36/375 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion Toliat et al. (1999); 848
E13795 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion Toliat et al. (1999)
E13332 Exon 4b 499delTGTT aa 167-168; PTC
176
4-bp deletion Toliat et al. (1999)
696 Exon 4b 527delA aa 176; PTC 177 1-bp deletion This report
1899 Exon 4b T528A D176E (Missense); polymorphism This report
2406 Exon 4b T528A D176E (Missense); polymorphism This report
190 Exon 4b T528A D176E (Missense); polymorphism Toliat et al. (1999); 545
702 Exon 4b T528A D176E (Missense); polymorphism Toliat et al. (1999); 849
422 Exon 4b T539A L180X Nonsense Toliat et al. (1999); 845
NF58a/124 Exon 4b 540insA Unequal expression aa 180; PTC 200 1-bp insertion Da¨schner et al. (1997);
97-003
1559 Exon 4b C574T Yes R192X Nonsense This report
380 Exon 4b C574T Yes Unequal expression R192X Nonsense Toliat et al. (1999); 847
1511 Intron 4b 5861delG Skip of exon 4b (?) Out of frame;
PTC 164
1-bp deletion; splice site This report
3399 Intron 4b 5861GrA No Skip of exon 4b (?) Out of frame;
PTC 164
Splice site This report
U-76 Intron 4b 5861GrA No Skip of exon 4b; unequal
expression
Out of frame;
PTC 164
Splice site This report
2395 Exon 4c T647C L216P Missense This report
U-61 Intron 4c 6552ArT Skip of exon 5 Out of frame;
PTC 255
Splice site This report
314 Intron 4c 6551GrA No Skip of exon 5 Out of frame;
PTC 255
Splice site Horn et al. (1996); 550
2048 Exon 5 703delTA aa 235; PTC 240 2-bp deletion This report
434 Exon 5 C715T (Yes) Q239X Nonsense Horn et al. (1996); 549
3358 Exon 6 754delT aa 252; PTC 280 1-bp deletion This report
2880 Exon 6 G801A No W267X Nonsense This report
1862 Exon 6 838delATAA aa 280-281; PTC
293
4-bp deletion This report
NF84a Exon 6 887delA Unequal expression aa 296; PTC 316 1-bp deletion This report
1008 Intron 6 8881GrA No Skip of exon 6 (?) Out of frame;
PTC 261
Splice site This report
3080 Intron 6 8881GrA No Skip of exon 6 (?) Out of frame;
PTC 261
Splice site This report
620 Intron 6 8892ArG Skip of exon 7 In frame; 58 aa Splice site Klose et al. (1999)
U-15 Exon 7 C910T* Yes Skip of exon 7; unequal
expression
R304X; in frame;
58 aa
(Nonsense); splice error Hoffmeyer et al.
(1998), 0156
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Patienta Location Sequence Changeb
CpGc
(CpNpG) RNA Leveld Protein Leveld,c Mutation Type
Reference;
NF1 Mutation
Database No.
2180 Exon 7 C910T* Yes Skip of exon 7 (?) R304X; in frame;
58 aa
(Nonsense); splice error This report
U-5 Exon 7 918delT No exon skipping aa 306; PTC 316 1-bp deletion Hoffmeyer et al.
(1998), 97-012
1815 Exon 7 918delT aa 306; PTC 316 1-bp deletion This report
1163 Exon 7 955delAG aa 319; PTC 328 2-bp deletion This report
3109 Exon 7 1019delCT aa 340; PTC 351 2-bp deletion This report
3293 Exon 7 1019delCT aa 340; PTC 351 2-bp deletion This report
737 Exon 7 1019delCT aa 340; PTC 351 2-bp deletion This report
750 Exon 7 A1060T K354X Nonsense This report
448 Exon 7 G1062A No Skip of exon 7; unequal
expression
K354K; inframe;
58 aa
(Silent); splice site This report
2719 Intron 7 106267TrC ? ? Splice error ? This report
2239 Intron 7 106313GrA No ? ? Splice error ? This report
2837 Exon 8 T1070C L357P Missense This report
256 Exon 8 1111insT aa 371; PTC 378 1-bp insertion This report
NF172 Intron 8 11851GrA No Skip of exon 8; unequal
expression
In frame;41 aa Splice site Hoffmeyer et al.
(1995); report w/o
no.
59 Intron 8 11851GrT Skip of exon 8 In frame;41 aa Splice site Horn et al. (1996); 551
889 Intron 8 11853insTAAA Skip of exon 8 (?) In frame;41 aa 4-bp insertion; splice site This report
763 Exon 9 T1224G Y408X Nonsense This report
U-51 Exon 9 C1246T Yes R416X Nonsense This report
NF56 Exon 9 C1246T Yes Unequal expression R416X Nonsense This report
1994 Exon 9 C1246T Yes R416X Nonsense This report
2413 Exon 9 C1246T Yes R416X Nonsense This report
1023 Exon 9 1255delA aa 419; PTC 472 1-bp deletion This report
248 Exon 10a G1275A No W425X Nonsense This report
U-65 Exon 10a C1318T Yes R440X Nonsense This report
1138 Exon 10a C1318T Yes R440X Nonsense This report
2349 Exon 10a C1318T Yes R440X Nonsense This report
1571 Exon 10a 1338delA aa 446; PTC 472 1-bp deletion This report
E11034 Exon 10a C1381T Yes R461X Nonsense This report
U-57 Exon 10b 1398insT aa 466; PTC 469 1-bp insertion This report
33 Exon 10b 1436insA aa 479; PTC 490 1-bp insertion This report
2788 Exon 10b A1466G Skip of the 3′ end of
Exon 10b (?)
Y489C; out of
frame; PTC
489
(Missense); splice error This report
250 Exon 10b A1472G Y491C Missense This report
936 Exon 10b A1472G Y491C Missense This report
1917 Exon 10b 1484delCC aa 495; PTC 509 2-bp deletion This report
2859 Exon 10b 1519insT aa 507; PTC 509 1-bp insertion This report
1288 Intron 10b 15271delG Skip of exon 10b (?) In frame; 45 aa 1-bp deletion; splice site This report
22 Exon 10c 1541delAG aa 514; PTC 556 2-bp deletion Robinson et al. (1996);
544
190 Exon 10c 1541delAG No exon skipping aa 514; PTC 556 2-bp deletion Robinson et al. (1996);
545
535 Exon 10c 1541delAG aa 514; PTC 556 2-bp deletion This report
1169 Exon 10c 1546delC aa 516; PTC 525 1-bp deletion This report
2243 Intron 10c 16411GrT Skip of exon 10c (?) In frame; 38 aa Splice site This report
3918 Intron 10c 16428ArG Exon 11 enlarged by 7
bp (?)
Out of frame;
PTC 559 (?)
Splice error This report
1003 Exon 11 T1646C L549P Missense This report
279 Exon 11 G1721C Skip of exon 11 (?) S574T; out of
frame; PTC
560
(Missense); splice site This report
945 Exon 11 G1721A No Skip of exon 11 (?) S574N; out of
frame; PTC
560
(Missense); splice site This report
1070 Intron 11 17213ArG Skip of exon 11 (?) Out of frame;
PTC 560
Splice site This report
1377 Intron 11 17213ArG Skip of exon 11 (?) Out of frame;
PTC 560
Splice site This report
3855 Exon 12a T1742C 1581T Missense This report
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NF1 Mutation
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1584 Exon 12a A1748G K583R Missense This report
1700 Exon 12a A1748G K583R Missense This report
3853 Exon 12a 1756delACTA aa 586-587;
PTC 603
4-bp deletion This report
2869 Exon 12a 1817insT aa 606; PTC 609 1-bp insertion This report
753 Intron 12a 18451delGTAAG Skip of exon 12a (?) Out of frame;
PTC 589
5-bp insertion;
splice site
This report
2273 Exon 12b 1935delG aa 645; PTC 687 1-bp deletion This report
2760 Exon 12b C1994T No S665F Missense This report
NF92 Exon 12b 1998insCCTCT aa 666; PTC 689 5-bp insertion Bo¨ddrich et al. (1995);
546
2889 Exon 13 2027delC aa 676; PTC 687 1-bp deletion This report
3259 Exon 13 2027insC aa 676; PTC 699 1-bp insertion This report
NF176 Exon 13 2033insC Unequal expression aa 678; PTC 699 1-bp insertion 97-014
212 Exon 13 C2041T* Yes R681X Nonsense This report
666 Exon 13 C2041T* Yes R681X Nonsense This report
2052 Exon 13 C2041T* Yes R681X Nonsense This report
3806 Exon 13 C2041T* Yes R681X Nonsense This report
2296 Exon 13 C2076G Y692X Nonsense This report
1982 Exon 13 T2084C L695P Missense This report
4132 Exon 13 2190delCCTCT aa 730-732;
PTC 734
5-bp deletion This report
520 Intron 13 225231ArT Polymorphism This report
E11225 Intron 13 225231ArT No exon skipping Polymorphism This report
E13339 Intron 13 225231ArT Polymorphism This report
168 Exon 14 2272delAG aa 758; PTC 766 2-bp deletion 552
173 Exon 14 T2288C L763P Missense 553
66 Exon 15 G2330C W777S Missense This report
640 Exon 15 C2339A T780K Missense 554
1137 Exon 15 A2342C H781P Missense This report
U-55 Exon 15 C2356T No Q786X Nonsense This report
1624 Exon 16 2427insGTCTT/2430delG aa 810; PTC 815 Insertion/deletion This report
U-62 Exon 16 C2446T Yes No exon skipping;
equal expression
R816X Nonsense This report
1551 Exon 16 C2446T Yes R816X Nonsense This report
2746 Exon 16 C2446T Yes R816X Nonsense This report
942 Exon 16 T2540C L847P Missense This report
NF213 Exon 16 2590insTATA Unequal expression aa 864; PTC 865 4-bp insertion Report w/o no.
2332 Exon 16 2666delC aa 889; PTC 901 1-bp deletion This report
633 Exon 16 2674delA aa 892; PTC 901 1-bp deletion This report
626 Exon 16 C2842T No Q948X Nonsense This report
1031 Exon 16 2844delA aa 948; PTC 953 1-bp deletion This report
3212 Exon 16 2845insT aa 949; PTC 955 1-bp insertion This report
2803 Exon 16 2850insTT aa 950; PTC 954 2-bp insertion This report
1742 Exon 17 2970delAAT aa 990-991;
991delM
3-bp deletion This report
E13563 Exon 17 2970delAAT aa 990-991;
991delM
3-bp deletion This report
NF183 Exon 17 2972insT Unequal expression aa 991; PTC 1020 1-bp insertion 97-013
U-88 Intron 17 29912ArG Skip of exon 18;
equal expression
In frame; 41 aa Splice site This report
646 Intron 17 29911GrA No Skip of exon 18;
equal expression
In frame; 41 aa Splice error This report
U-27/507 Intron 17 29911GrC Skip of exon 18;
equal expression
In frame; 41 aa Splice site This report
3365 Exon 18 T2994A Y998X Nonsense This report
858 Exon 18 3060delA aa 1020; PTC 1021 1-bp deletion This report
223 Exon 19a 3178delG aa 1060; PTC 1061 1-bp deletion This report
NF23 Exon 19a 3193insA aa 1065; PTC 1087 1-bp insertion Klose et al. (1998c);
440
1572 Exon 20 3394insAG aa 1132;
PTC 1142
2-bp insertion This report
3400 Exon 20 3456delACTC aa 1152-1153;
PTC 1156
4-bp deletion This report
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255 Exon 20 3456delACTC aa 1152-1153;
PTC 1156
4-bp deletion This report
460 Exon 20 3456delACTC aa 1152-1153;
PTC 1156
4-bp deletion This report
3809 Exon 20 A3467G* N1156S Missense This report
520 Intron 20 34962TrC Skip of exon 20 Out of frame;
PTC 1133
Splice site Klose et al. (1998c);
444
1747 Exon 21 3525delAA aa 1175-1176;
PTC 1193
2-bp deletion This report
2861 Exon 21 3525delAA aa 1175-1176;
PTC 1193
2-bp deletion This report
3340 Exon 21 G3628T E1210X Nonsense This report
878 Exon 21 3643delATG 1215delM 3-bp deletion This report
2340 Exon 21 G3707A No W1236X Nonsense This report
742 Exon 22 C3721T* Yes No exon skipping R1241X Nonsense This report
2266 Exon 22 3737delTGTT aa 1246-1247;
PTC 1264
4-bp deletion This report
1528 Exon 22 G3749C R1250P Missense This report
76 Exon 22 G3773A (Yes) W1258X Nonsense This report
51 Exon 22 3822delCT aa 1274-1275;
PTC 1282
2-bp deletion This report
1186 Exon 22 C3826T* Yes R1276X Nonsense This report
157 Exon 22 C3826T* Yes R1276X Nonsense Klose et al. (1998b);
441
U-63 Exon 22 C3826T* Yes R1276X Nonsense This report
1899 Exon 22 G3827A Yes R1276Q Missense This report
1939 Exon 22 G3827A Yes R1276Q Missense This report
364 Exon 22 G3827C No exon skipping R1276P Missense Klose et al. (1998a);
442
288 Exon 22 C3831T No G1277G Silent This report
2235 Exon 23-1 3909dclT aa 1303; PTC 1308 1-bp deletion This report
578 Exon 23-1 3911dclT aa 1304; PTC 1308 1-bp deletion This report
258 Exon 23-1 C3916T Yes “CpG, RNA editing site” R1306X Nonsense This report
2601 Exon 23-1 C3916T Yes “CpG, RNA editing site” R1306X Nonsense This report
71 Exon 23-1 C3916T Yes “CpG, RNA editing site” R1306X Nonsense This report
3979 Exon 23-1 C3916T Yes “CpG, RNA editing site” R1306X Nonsense This report
82 Intron 23-1 39752ArG Skip of exon 23-2;
equal expression
Out of frame;
PTC 1339
Splice site This report
796 Exon 23-2 C4006T (Yes) Q1336X Nonsense This report
471 Exon 23-2 4016delT aa 1339; PTC 1342 1-bp deletion This report
206 Exon 23-2 C4084T Yes No exon skipping R1362X Nonsense This report
415 Exon 23-2 C4084T Yes R1362X Nonsense This report
E13562 Intron 23-2 41101GrC Skip of exon 23-2;
unequal expression
Out of frame;
PTC 1339
Splice site This report
U-19 Exon 24 G4243T E1415X Nonsense This report
1765 Exon 24 4247ins74-bp from
intron 25
aa 1416; PTC 1422 74-bp insertion This report
895 Exon 25 T4274C L1425P Missense This report
219 Exon 25 T4274C L1425P Missense Peters et al. (1999a)
278 Exon 25 4311delAGAA aa 1437-1438;
PTC 1446
4-bp deletion This report
238 Intron 25 436846GrC rare variant This report
333 Intron 25 43681GrT Skip of exon 26 In frame; 49 aa Splice site This report
3745 Exon 26 4374insT aa 1459; PTC 1460 1-bp insertion This report
1517 Exon 26 4431delC aa 1477; PTC 1478 1-bp deletion This report
U-77 Exon 26 G4473A No W1491X Nonsense This report
31 Exon 26 4486delA aa 1496; PTC 1552 1-bp deletion This report
U-66 Exon 26 4497insG aa 1499; PTC 1508 1-bp insertion This report
831 Intron 26 45141GrA No Skip of exon 26 (?) In frame; 49 aa Splice site This report
2928 Intron 26 45152ArG Skip of exon 27a (?) In frame; 49 aa Splice site This report
U-39 Exon 27a C4537T* Yes R1513X Nonsense This report
U-40 Exon 27a C4537T* Yes R1513X Nonsense This report
401 Exon 27a C4537T* Yes R1513X Nonsense This report
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803
Table 4 Continued
Patienta Location Sequence Changeb
CpGc
(CpNpG) RNA Leveld Protein Leveld,c Mutation Type
Reference;
NF1 Mutation
Database No.
740 Exon 27a C4537T* Yes R1513X Nonsense This report
2488 Exon 27a C4537T* Yes R1513X Nonsense This report
2713 Exon 27a C4537T* Yes R1513X Nonsense This report
2789 Exon 27a C4537T* Yes R1513X Nonsense This report
U-87a Exon 27a G4614A No W1538X Nonsense This report
966 Exon 27a 4649insG aa 1550; PTC
1554
1-bp insertion This report
U-29 Exon 27b 4703delC aa 1558; PTC
1569
1-bp deletion This report
1784 Exon 27b C4719G Y1573X Nonsense This report
2646 Exon 27b A4750G 11584V Missense This report
486 Exon 28 T4839G No exon skipping; une-
qual expression
Y1613X Nonsense Peters et al. (1999b);
97-001
3696 Exon 28 4936insT aa 1646; PTC
1660
1-bp insertion This report
56 Exon 28 5050delAGGCTTG aa 1684-1686;
PTC 1686
7-bp deletion This report
102 Exon 28 5055insT aa 1686; PTC
1696
1-bp insertion Peters et al. (1999b);
450
345 Exon 28 A5106G Q1702Q Silent Peters et al. (1999b)
734 Exon 28 5152delG aa 1718; PTC
1725
1-bp deletion This report
B-212 Exon 28 5168delTC aa 1723; PTC
1734
2-bp deletion Peters et al. (1999b);
842
342 Exon 28 G5172A No K1724K Silent Peters et al. (1999b)
186 Exon 28 G5172A No K1724K Silent Peters et al. (1999b)
B-250 Exon 28 5205delAGTAA Skip of exon 28 (?) Out of frame;
PTC 1599
5-bp deletion; splice site Peters et al. (1999b);
97-002
1218 Exon 29 C5242T Yes R1748X Nonsense This report
2886 Exon 29 C5242T Yes R1748X Nonsense This report
U-34/40 Exon 29 C5242T Yes No exon skipping R1748X Nonsense Peters et al. (1999b);
97-011
68 Exon 29 5248delAAA 1750delK 3-bp deletion This report
1079 Exon 29 T5286G Y1762X Nonsense This report
388 Exon 29 C5329T (Yes) Q1777X Nonsense This report
528 Exon 29 T5339A L1780X Nonsense This report
1698 Exon 29 T5339A L1780X Nonsense This report
3443 Exon 29 C5353T (Yes) Q1785X Nonsense This report
1038 Exon 29 5399delT aa 1800; PTC
1841
1-bp deletion This report
63 Exon 29 C5458T No Q1820X Nonsense Peters et al. (1999b);
97-010
3344 Exon 29 5484delT aa 1828; PTC
1841
1-bp deletion This report
U-25/702 Exon 29 G5546A Yes Skip of exon 29 R1849Q; Out of
frame; PTC
1740
(Missense); splice site This report
1990 Exon 29 G5546A Yes Skip of exon 29 (?) R1849Q; Out of
frame; PTC
1740
(Missense); splice site This report
2191 Intron 29 55461GrA (Yes) Skip of exon 29 (?) Out of frame;
1740
Splice site This report
NF113 Intron 29 55462TrG Skip of exon 29; unequal
expression
Out of frame;
PTC 1740
Splice site report w/o no.
1164 Exon 30 5584delAC aa 1862; PTC
1863
2-bp deletion This report
527 Exon 30 5592delTTTAA aa 1864-1866;
PTC 1889
5-bp deletion Harder et al. ((1999));
439
224 Exon 31 C5839T Yes R1947X Nonsense Klose et al. (1999); 437
1197 Exon 31 C5839T Yes R1947X Nonsense This report
2672 Exon 31 C5839T Yes R1947X Nonsense This report
394 Exon 31 5847delAG aa 1949-1950;
PTC 1954
2-bp deletion This report
2097 Intron 31 59431GrA No Skip of exon 31 (?) Out of frame;
PTC 1922
Splice site This report
(continued)
Table 4 Continued
Patienta Location Sequence Changeb
CpGc
(CpNpG) RNA Leveld Protein Leveld,c Mutation Type
Reference;
NF1 Mutation
Database No.
472 Intron 31 59445ArG Skip of exon 32 (?) In frame; 47 aa Splice site This report
1215 Intron 31 59442ArG Skip of exon 32 (?) In frame; 47 aa Splice site This report
2369 Exon 33 6220delG aa 2074; PTC 2089 1-bp deletion This report
2774 Exon 34 6468delC aa 2156; PTC 2178 1-bp deletion This report
608 Exon 34 6470delT aa 2157; PTC 2178 1-bp deletion This report
2912 Exon 34 6471delC aa 2157; PTC 2178 1-bp deletion This report
16 Exon 34 T6566A L2189X Nonsense This report
U-64 Intron 34 65792TrG Skip of exon 34;
unequal expression
Out of frame;
PTC 2148
Splice site This report
1126 Intron 34 657945TrA ? ? Splice error ? This report
514 Intron 34 657987GrA No ? ? Splice error ? This report
2086 Exon 35 6604delT aa 2202; PTC 2211 1-bp deletion This report
234 Exon 35 G6628T E2210X Nonsense This report
3568 Intron 35 66412delT Skip of exon 35 (?) Out of frame;
PTC 2199
1-bp deletion; splice site This report
2406 Intron 35 6642-1GrT Skip of exon 36 (?) Out of frame;
PTC 2220
Splice site This report
1832 Exon 36 C6709T Yes R2237X Nonsense This report
U-67/572 Exon 36 C6709T Yes R2237X Nonsense This report
3634 Exon 36 C6709T Yes R2237X Nonsense This report
952 Intron 36 67561GrA No Skip of exon 36 (?) Out of frame;
PTC 2220
Splice site This report
NF33 Exon 37 6789delTTAC aa 2263-2264;
PTC 2268
4-bp deletion Hoffmeyer et al. (1998)
U116 Exon 37 6789delTTAC No exon skipping aa 2263-2264;
PTC 2268
4-bp deletion Robinson et al (1995);
543
342 Exon 37 6789delTTAC No exon skipping;
equal expression
aa 2263-2264;
PTC 2268
4-bp deletion Bo¨ddrich et al. (1997);
547
1706 Exon 37 6789delTTAC aa 2263-2264;
PTC 2268
4-bp deletion This report
3467 Exon 37 6789delTTAC aa 2263-2264;
PTC 2268
4-bp deletion This report
407 Exon 37 6790insTT No exon skipping;
equal expression
aa 2264;
PTC 2270
2-bp insertion Bo¨ddrich et al. (1997);
548
1354 Exon 37 6791insA aa 2264; PTC 2285 1-bp insertion This report
25 Exon 37 C6792A Skip of exon 37;
equal expression
Y2264X; in frame;
34 aa
(Nonsense); splice error Robinson et al. (1995);
541
1 Exon 37 C6792A Skip of exon 37;
equal expression
Y2264X; in frame;
34 aa
(Nonsense); splice error Robinson et al. (1995);
542
E11225 Exon 37 C6792A Skip of exon 37;
equal expression
Y2264X; in frame;
34 aa
(Nonsense); splice error This report
1828 Exon 37 C6792G Skip of exon 37 (?) Y2264X; in frame;
34 aa
(Nonsense); splice error This report
2472 Exon 37 6792insA aa 2265; PTC 2285 1-bp insertion This report
U-43/547 Exon 37 6797delGT No exon skipping aa 2266; PTC 2284 2-bp deletion This report
1920 Exon 37 T6839G L2280X Nonsense This report
3110 Exon 39 7080insA aa 2361; PTC 2364 1-bp insertion This report
3578 Exon 39 7095delT aa 2365; PTC 2374 1-bp deletion This report
E15470 Exon 40 7208delGA aa 2403; PTC 2405 2-bp deletion This report
260 Exon 40 C7237T (Yes) Q2413X Nonsense This report
61 Exon 40 G7258C Skip of exon 40 (?) A2420P; in frame;
44 aa
(Missense); splice site This report
B-214 Intron 40 725917CrT No ? ? Splice error? 841
B-212 Intron 40 725914CrT Yes rare variant 842
400 Exon 41 7268delCA aa 2423; PTC 2425 2-bp deletion This report
3541 Exon 41 7285delC aa 2429; PTC 2434 1-bp deletion This report
1777 Exon 41 C7285T Yes R2429X Nonsense This report
E14377 Exon 41 C7285T Yes R2429X Nonsense This report
E14071 Exon 41 7367delCC aa 2456; PTC 2460 2-bp deletion This report
395 Intron 41 73951GrA (Yes) Skip of exon 42 (?) Out of frame;
PTC 2471
Splice site 850
U-20/9723 Exon 42 CT7424AG S2475X Nonsense This report
1000 Exon 42 C7457T No T24861 Missense This report
934 Exon 42 C7486T Yes R2496X Nonsense This report
2717 Exon 42 C7486T Yes R2496X Nonsense This report
(continued)
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Patienta Location Sequence Changeb
CpGc
(CpNpG) RNA Leveld Protein Leveld,c Mutation Type
Reference;
NF1 Mutation
Database No.
U-46 Exon 42 7528ins1 bp Duplication of bases
7515-7528
aa 2510; PTC 2531 14-bp insertion This report
698 Exon 42 7544insGA aa 2515; PTC 2527 2-bp insertion This report
2714 Exon 43 7569delT aa 2523; PTC 2526 1-bp deletion This report
1675 Exon 43 7633insC aa 2545; PTC 2555 1-bp insertion This report
U-87b Exon 44 C7699T No Q2567X Nonsense This report
2253 Exon 44 A7701G Q2567Q Silent This report
90 Exon 44 C7702T (Yes) Q2568X Nonsense This report
2973 Exon 44 C7702T (Yes) Q2568X Nonsense This report
2569 Exon 45 C7846T Yes R2616X Nonsense This report
383 Intron 45 79071GrA No Skip of exon 45 Out of frame;
PTC 2604
Splice site 555
735 Intron 45 7908-2ArG Skip of exon 46 (?) Out of frame;
PTC 2640
Splice site This report
1480 Exon 46 7926insT aa 2643; PTC 2643 1-bp insertion This report
2499 Exon 46 8024delC aa 2675; PTC 2717 1-bp deletion This report
578 Intron 46 805020ArG No exon skipping Polymorphism This report
586 Intron 46 508020ArG Polymorphism This report
U-82/310 Exon 47 8092insTT aa 2698; PTC 2718 2-bp insertion This report
a The same patient may have different ID numbers because some patients were included in both the PTT and the TGGE screening panels.
Some patients appear twice in the list because two separate sequence changes were identified (see table 5).
b Numbering system based on NF1 cDNA (Genbank M82814), 1 = first base of methionine (ATG) at start of cDNA. The asterisk indicates
congruence to NF1 pseudogene sequences: C910T to D26141/AC004527 (#21); C2041T to U35696 (#14); A3467G, C3721T, C3826T, and
C4537T to M84131 (#15).
c All GrA and CrT transitions were checked to see whether they occurred in a CpG or a CpNpG motif. In the latter case, “yes” was put
in parentheses.
d A question mark in parentheses means “predicted but not tested.” A question mark without parentheses means “highly speculative” and
that the underlying mutations were not considered pathogenic.
e In the case of frameshift mutations, the affected amino acid (aa) positions are given, as well as the position of the premature termination
codon (PTC) in the predicted aberrant polypeptide. In the case of in-frame deletions caused by exon skipping, the number of amino acids (aa)
expected to be lost in the predicted aberrant polypeptide is given.
tient. The total number of different mutations identified
was 216. Among the recurrent mutations, the threemost
common were R1513X in exon 27a (7 patients),
499delTGTT in exon 4b (6 patients), and 6789delTTAC
in exon 37 (five patients). Furthermore, we found that
216 of our mutations, of which 179 were different, were
not listed in the most recent review in the field (Upa-
dhyaya and Cooper 1998). Overall, the total number of
different minor lesion mutations of the NF1 gene de-
scribed to date well exceeds 276, because 97 other mu-
tations of this type have been published before (Upa-
dhyaya and Cooper 1998) and some more unpublished
mutations have been reported to the International NF1
Genetic Analysis Consortium.
Distribution of NF1 Mutations
To get an idea of their distribution over theNF1 gene,
we plotted the 278 pathogenic mutations exon by exon
into a diagram (fig. 1). Intronic mutations were allocated
to the nearest exon. Direct comparison with the 173
minor lesions that had been reported to the International
NF1 Genetic Analysis Consortium by November 1997
(Korf 1998) (white columns in fig. 1) underscores the
strong bias towards central parts of the NF1 gene in-
herent in these data. In particular, exons 28–36—the 9
exons that were described first (Cawthon et al.
1990)—and the GRD region were analyzed in hundreds
of NF1 patients by the consortium members, whereas
exons of other regions, mainly at the 5′ end of the gene,
were not investigated at all. In our study, all parts of the
gene were analyzed with equal intensity. Thus, we sup-
pose our data to be an approximate representation of
the actual distribution of mutations over the NF1 gene,
at least in our study population, which is mainly of
German origin, but includes also some patients of Turk-
ish extraction. As indicated by figure 1, it appears likely
that all regions of the NF1 gene are subject to mutation
to a similar extent. However, if data are weighed for
exon size (fig. 2a), exons 4b and 37 stand out as sites
of a remarkably high mutation density. The reason for
this may be found in some structural elements prone to
mutation, a short tandem repeat structure in exon 4b
(Toliat et al. 1999) and a quasisymmetric element in
exon 37 (Robinson et al. 1995; Bo¨ddrich et al. 1997).
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Figure 1 Histogram of number of mutations, exon by exon. Black columns represent the 278 pathogenic mutations of table 4. White
columns represent the mutations reported to the NF1 Genetic Analysis Consortium as of November 1997 (Korf 1998).
If presented in a logarithmic mode (fig. 2b), the data
reveal a slight tendency to fewer mutations towards the
3′ end of the gene that may be caused by the distribution
of the missense mutations, as discussed later. Further-
more, several exons are easily recognized in which no
mutation was found (exons 9br, 19b, 23a, 38, and
48–49) or that are extremely underrepresented (exons
4a and 33).
Cryptic Splice Mutations
We identified a total of 55 splicing-error mutations
(19.8% of all the mutations we found). In 22 cases, an
exon skip was revealed in the patients’ mRNA. Several
mutations were found to affect the splicing process, al-
though they do not pertain to the group of typical splice-
site mutations. At first glance, many of these were in-
terpreted as faults, but analysis of mRNA as part of the
PTT made us aware of the problem, and we initiated a
routine checking of mRNA in all ambiguous cases (if
mRNA was available). As reported elsewhere (Hoff-
meyer et al. 1998), the two nonsense mutations (R304X
and Y2264X) result in a skipping of exons 7 and 37,
respectively. The mutation Y2264X may be caused by
either of two transversions, C6792A or C6792G, both
of which result in skipping of exon 37 (Messiaen et al.
1997). Five other nonsense mutations, as well as six
small deletions or insertions, were also tested thor-
oughly, but did not show any influence on the splicing
process (see table 4). However, in addition to the non-
sense mutations, we identified a silent mutation (K354K)
and several missense mutations (Y489C, S574T, S574N,
R1849Q, and A2420P) that also cause exon skipping,
presumably or definitely (see table 4). Most of these
mutations affect the last base of the exon that is part of
the splice donor and is usually a guanine (Krawczak et
al. 1992). Messiaen et al. (1998) reported that mutation
Y489C generates a new splice donor converting the 3′
end of exon 10b into an intronic sequence that is sub-
sequently removed during splicing as part of intron 10b.
The mutation Y491C might act in the same manner;
however, no mRNA was available to test this possibility.
Two Sequence Changes
All 60 exons were analyzed in all patients; therefore,
multiple sequence changes should have been identified
if present. In addition to the known biallelic polymor-
phisms in exons 5 (702A/G) and 13 (2034G/A) and those
in introns 28 (520523C/T) and 41 (7395-29A/G), we
identified three novel biallelic polymorphisms: 1528-
29delT, 164139C/T, and 3315-130G/C (located in in-
trons 10b, 10c, and 19b, respectively) with allele fre-
quencies higher than 30% for both alleles. The frequent
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Figure 2 Weighed distribution of mutations over the NF1 gene. For each exon, the number of pathogenic mutations was divided by the
number of base pairs (bp). Ten bp were added to each exon, to allow for splice-site mutations. Values shown are ratios between the exon-
specific mutation densities and the average mutation density for the whole gene (278/9,204 bp).A, linear presentation.B, logarithmicpresentation.
polymorphisms were not taken into account when look-
ing for additional sequence changes in theNF1 gene, yet
two rare sequence changes were found in 10 of the pa-
tients (table 5). Determining which change is pathogenic
is straightforward if a truncating mutation is observed
among them; however, the occurrence of two pathogenic
mutations is possible. We tested the mutations 2252-
31ArT and 805020ArG for their influence on the
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Table 5
Patients with Two Sequence Changes in the NF1 Gene
Patient First Sequence Change, Nonpathogenic Second Sequence Change, Pathogenic
1899 T528A = D176E (exon 4b) G3827A = R1276Q (exon 22)
2406 T528A = D176E (exon 4b) 6642-1GrT (intron 35)
190 T528A = D176E (exon 4b) 1541delAG (exon 10c)
702 = U-25 T528A = D176E (exon 4b) G5546A = R1849Q (skip of exon 29)
520 2252-31ArT (intron 13) 34962TrC (intron 20)
E11225 2252-31ArT (intron 13) C6792A = Y2264X (skip of exon 37)
342 G5172A = K1724K (exon 28) 6789del4bp (exon 37)
B-212 7259-14CrT (intron 40) 5168delTC (exon 28)
2253 A7701G = Q2567Q (exon 44) T482A = L161X (exon 4b)
578 805020ArG (intron 46) 3911delT (exon 23-1)
splicing process, but no exon skipping was observed. In
the case of patient 1899, a choice between two missense
mutations, D176E and R1276Q, was necessary; the po-
sition of the latter gives a helpful hint. Arg1276 is the
arginine finger of the GRD—the most essential catalytic
element for RasGAP activity. Its mutation into proline
was shown to completely disable GAP activity without
impairing the secondary and tertiary protein structure
(Klose et al. 1998a). Mutation R1276Q compromises
GAP-stimulated GTP hydrolysis some 500-fold (Ah-
madian et al. 1997). Compared with the 8,000-fold re-
duction by mutation R1276P (Klose et al. 1998a), this
is still a remarkable residual activity. However, it may
be sufficient to cause NF1, because other missense mu-
tations of the GRD with moderate reduction of GAP
activity have already been reported (Kim and Tamanoi
1998). It is tempting to speculate about a modifying
effect of D176E on the NF1 phenotype. This might occur
in cis as well as trans to another missense mutation or
in trans to any other pathogenic mutation. In the in-
stance of patient 1899, it is not known whether D176E
and R1276Q are situated on the same allele or on dif-
ferent alleles. In the other three cases, both sequence
changes cosegregate; that is, D176E is in cis to a trun-
cating mutation, with little or no chance of exerting an
effect on the phenotype because of the absence of the
mutant gene product normally observed with this type
of mutation (Hoffmeyer et al. 1995). Recently, we an-
alyzed the unaffected father of patient 702, who is a
sporadic case himself. Because the father is also a carrier
of D176E, we were able to determine that this amino
acid exchange alone is not sufficient to cause NF1.
CpG Mutations
CpG dinucleotides show a high mutation rate in the
human genome caused by spontaneous deamination of
5-methylcytosine; ∼25% of all single base-pair substi-
tutions involve this dinucleotide (Cooper and Krawczak
1993). In the coding region of the NF1 gene, there are
118 CpGs, and a CrT transition on either the coding
or noncoding strand of 91 of these would result in a
disease-related mutation (Krkljus et al. 1997). Methyl-
ation of CpGs is a prerequisite for this type of mutation.
Interestingly, methylated CpGs have been reported to
occur within and around the NF1 gene; for example,
92% of CpGs in exons 28, 29, and 31 were found to
be methylated in sperm DNA (Rodenhiser et al. 1993;
Andrews et al. 1996). This prompted us to check our
data for typical CpG mutations. Among the 301 se-
quence changes, we identified 57 (18.9%) CrT or GrA
transitions within a CpG dinucleotide (table 4). The 301
sequence changes include 181 single base-pair substi-
tutions, and only 31.5% of these represent a typical CpG
mutation. Twenty-one different CpGs from the coding
region are involved; that is, 17.8% of the 118 CpGs
present in the coding region. They include 1 silent, 2
missense, and 18 nonsense mutations. One of these CpG
mutations, R1513X, is the most frequently observed re-
current mutation among all 278 mutations. In addition
to CpGs, we identified 9 CpNpG motifs that were sub-
ject to a CrT or GrA transition in 10 patients. Although
DNA methylation at these sites has also been reported
(Clark et al. 1995), it is evident from our data that they
do not play a significant role in NF1 mutagenesis.
Relations to Pseudogene Variants
Genetic variation within pseudogenes may serve as a
template for pathological lesions in the original gene by
means of gene conversion even if located on different
chromosomes (Eikenboom et al. 1994). In view of the
large number of NF1 pseudogenes, it has been hypoth-
esized that they are reservoirs of preformed mutations
and may account for the high mutation rate of the NF1
gene (Cummings et al. 1993). Therefore, we analyzed
all NF1-like sequences available from the public data-
bases for any sequence deviation from the authenticNF1
gene. We located 31 entries (table 6) and identified 235
discrepancies (of which 196 were different) between the
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Table 6
NF1 Pseudogene Sequences in the Public Databases
Accession Number Exons Chromosome Reference
AC004527 7–9 21 R. B. Weiss et al.,a unpublished data
D26141 7–11 21 H. Suzuki, unpublished data
U35688 8 18 Purandare et al. (1995)
U35689 9 18 Purandare et al. (1995)
U35696 13 18 Purandare et al. (1995)
YO7853 13–15 17 Re´gnier et al. (1997)
YO7854 13–15 14 Re´gnier et al. (1997)
YO7855 13–15 14 Re´gnier et al. (1997)
YO7856 13–15 15 Re´gnier et al. (1997)
YO7857 13–15 15 Re´gnier et al. (1997)
YO7858 13–15 2 Re´gnier et al. (1997)
YO7859 13–15 22 Re´gnier et al. (1997)
AF011743 14 15q11.2 Kehrer-Sawatzki et al. (1997)
AF011744 15 15q11.2 Kehrer-Sawatzki et al. (1997)
AF011746 15 15q11.2 Kehrer-Sawatzki et al. (1997)
U35684 15 14 Purandare et al. (1995)
U35685 15 15 Purandare et al. (1995)
U35686 16 12 Purandare et al. (1995)
U35687 16 14 Purandare et al. (1995)
U35690 18 14 Purandare et al. (1995)
U35691 18 15 Purandare et al. (1995)
U35692 18 22 Purandare et al. (1995)
U35693 19b 15 Purandare et al. (1995)
M84131 20–22 15 Legius et al. (1992)
AF011748 21 15q11.2 Kehrer-Sawatzki et al. (1997)
U35694 23-1 15 Purandare et al. (1995)
U35695 24 15 Purandare et al. (1995)
AF011745 24 15q11.2 Kehrer-Sawatzki et al. (1997)
AF011747 24 15q11.2 Kehrer-Sawatzki et al. (1997)
AF011749 24 15q11.2 Kehrer-Sawatzki et al. (1997)
X72619 24 15q24-qter Gasparini et al. (1993)
M84131 25–27b 15 Legius et al. (1992)
a Unpublished data from R. B. Weiss, D. M. Dunn, A. Aoyagi, L. Banks, B. Duval, C.
Hamil, C. Holmes, M. Mahmoud, R. Rose, R. Stokes, M. D. Stump, P. Yu, L. Zhou, Y.
Gitin, J. Nelson, and A. von Niederhausen.
sequences of the pseudogenes and the NF1 gene (not
shown). Only 6 (3.1%) of the 196 pseudogene variations
were also found among the NF1 mutations in table 4
(indicated by an asterisk); however, 4 of the 6 were re-
current mutations (including R1513X, which was found
in seven patients). Unfortunately, all but 1 of the 18
mutations with a pseudogene equivalent happened to
occur at highly mutable CpG sites (see above). This def-
initely weakens further the evidence of NF1 gene con-
version. Moreover, for gene conversion to explain the
high mutation rate, mutations should predominantly af-
fect the central part of the gene, which is not the case.
Missense Mutations
Formally, we identified a total of 39 missense muta-
tions or deletions of single amino acids. However, as
discussed earlier, D176E has to be considered a poly-
morphism, and others were shown to be splice muta-
tions. Furthermore, substitution of threonine for the first
methionine will cause a false start in translation, with
one of the following methionines acting as the initiation
codon (Neote et al. 1990; Patten et al. 1990). Hence,
strictly speaking, only 28 are genuine missense muta-
tions causing changes or losses of a particular amino
acid in the polypeptide chain. The distribution of these
mutations is shown in figure 3. It is evident that the
mutations cluster in two regions: the GRD, and up-
stream between exons 10b and 17. If we assume the
mutation Y491C to be a splice mutation like Y489C
(see above), this region would shrink even further, to an
interval from exon 11 to exon 17. Interestingly, a total
of 11 substitutions into proline (39%) were found
among the 28 missense mutations. Proline is known to
destabilize helices and beta sheets.
Except for patient 1899, who carries two missense
mutations, R1276Q and D176E, all of the other 28 gen-
uine missense mutations turned out to be the only se-
quence change present in the entire NF1 gene. This sug-
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Figure 3 Weighed distribution of missense mutations over the NF1 gene. For each exon, the number of genuine missense or single-amino-
acid-deletion mutations was divided by the number of base pairs (bp). Values shown are ratios between the exon-specific mutation densities
and the average mutation density for the whole gene (28/8457 bp). Location of the GRD is indicated by the box.
gests that these mutations cause the disease, yet further
evidence is needed to verify this hypothesis. To date,
functional and structural assessment of particular amino
acids has been obtained only for the GRD. For other
regions, information about evolutionary conservation
may help to evaluate the significance of an amino acid
exchange. Therefore, we generated an amino acid se-
quence alignment (program PILEUP of the GCG-Wis-
consin package, version 9; gap weight 12 and gap length
weight 4) between the sequences of the human and the
Drosophila NF1 proteins that are 60% identical over
their entire length (The et al. 1997). As many as 15 of
the 23 amino acid positions affected by missense mu-
tation in our patients with NF1 turned out to be invar-
iant, whereas, at two further positions, the amino acids
were replaced by similar ones in the Drosophila protein
(Ile1584 by Val and Arg1250 by Lys). At the other six
positions nonconservative substitutions were found or
the alignment generated a gap in theDrosophila protein
(Y491: M; K583: Q; S665:; H781: F; M1215: I;
T2486:). Moreover, we performed a similarity plot be-
tween the human and Drosophila sequences. Most of
the mutations are situated on top of the similarity peaks
or, at least, in regions of higher similarity, which may
represent helices or beta sheets (fig. 4). Exceptions are
Y491C—which might, in fact, be a splice muta-
tion—S665F, and T2486I. These findings raise the pos-
sibility that the latter two mutations may actually be
nonpathogenic.
Discussion
The systematic analysis of germline mutations in NF1
patients has been a major challenge for many labora-
tories during the last couple of years. Here, we present
for the first time a comprehensive screen of minor lesions
of the NF1 gene in a large cohort of 1500 unrelated
patients that is free of any assessment bias for special
exons or regions. We launched this project hoping that
the data would allow us to answer some long-standing
questions about the NF1 gene and its proneness to mu-
tate. Some of the questions were answered, but new
questions were raised as well.
The Mutational Spectrum
A preponderance of truncating mutations is one of the
most prominent features of NF1 mutations. Some 80%
of all small lesions result in a PTC; that is, about one
half of all NF1 mutations may be direct- or indirect-
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Figure 4 Missense mutations in the similarity plot of human versus Drosophila NF1 protein. The program PLOTSIMILARITY of the
GCG-Wisconsin package, version 9 was used to calculate the amino-acid-sequence similarity profile of the human andDrosophilaneurofibromins
(accession numbers AAA59925 and AAB58976, respectively). A sliding window of 40 amino acids was chosen. Note that there are 2,963
instead of 2,839 amino acid positions in the alignment (program PILEUP; gap weight = 12 and gap-length weight = 4). For the first 20 and
the last 20 positions, a value could not be calculated, because of the chosen window size. Mutations are located primarily in regions of higher
similarity. Usually, helices and beta sheets have a higher local sequence similarity than coils.
stop mutations. Distribution of this type of mutation is
very even over the coding sequence. We identified the
first one in exon 1 and the last in exon 47. At first glance,
no difference in phenotype was observed; however, a
detailed analysis of a possible relation between clinical
features and position of the PTC is in progress and will
be presented elsewhere (S. Tinschert, A. Buske, B.
Mu¨ller-Myhsok, I. Naumann, C. Mischung, R. Fahsold,
S. Hoffmeyer, D. Kaufmann, H. Peters, P. Nu¨rnberg,
unpublished data). Unequal expression of both NF1 al-
leles is a common observation in NF1 and has been
related to the high number of truncating mutations
(Hoffmeyer et al. 1995). This might explain the absence
of a position effect of PTCs; however, we also observed
equal expression in some cases, including patients U-62,
82, 342, and 407 (table 4). Of all mutations identified
in this study, ∼20% were splice defects, with nearly one-
half of the latter causing in-frame exon skipping. Hence,
analysis of mRNA, in combination with a PTC screening
as performed in the PTT, is a good choice for mutation
detection in NF1. In our hands, the detection rate was
47.1%, which is lower than the 67% detection rate orig-
inally reported (Heim et al. 1995) but in line with the
genomic-screening methods applied in this study, taking
into account the fact that missense mutations cannot be
detected by this approach. According to our data, mis-
sense mutations represent ∼10% of all small NF1
lesions.
The identification of a recurrent NF1 mutation has
often been heralded as the discovery of a mutation hot-
spot. The most widely known example is the mutation
R1947X in exon 31 (Valero et al. 1994; La´zaro et al.
1995). At least 10 unrelated patients with NF1, among
563 tested, were reported to carry this mutation (recur-
rence rate ∼2%) (Upadhyaya and Cooper 1998). In our
screening of 521 unrelated patients with NF1, however,
only 3 presented with this mutation. The most frequent
mutation in our study was R1513X in exon 27a found
in seven patients. However, when looking for the highest
density of mutations, exons 4b and 37 outnumbered all
other exons with a value 4- to 5-fold higher than av-
erage. This suggests these exons include someminor hot-
spots. Nevertheless, with the large number of novel mu-
tations presented in this paper, it becomes obvious that
Figure 5 Synopsis of all known NF1 missense mutations and deletions of 1 or 2 amino acids. Mutations on the left and right sides are
data from this study and from the literature, respectively. Most published mutations have been reviewed in Upadhyaya and Cooper (1998).
Some have been published very recently: R1204G (Krkljus et al. 1997); C39Y(1), Y489C, L847P, and 991delM(1) (Messiaen et al. 1998); and
L2317P (Wu et al. 1999). Others have been submitted to the consortium but not published at this time. They are reported here with the consent
of the consortium members who identified these mutations: 2366delNF(2) and R2616Q (L. Messiaen, personal communication); R1849G and
L1932P (M. Upadhyaya, personal communication); 1658delIY and P2046R (D. Vidaud, personal communication). Mutations not representing
genuine missense mutations including polymorphisms, splice mutations, or loss of the initiation codon are printed in italics. Number in parentheses
after the mutation symbol indicates recurrent identifications. GRD region is shown in gray, whereas the exons 11–17, supposed to code for a
new functional domain, are shown in black with a central light effect. To facilitate orientation, the numbers of some of the larger exons are
given.
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the worst-case scenario is operating: hundreds of private
mutations for most of the families affected by NF1. In-
terestingly, all three alternatively spliced exons—9br,
23a, and 48a—seem to be irrelevant to mutation anal-
ysis. Likewise, two normally spliced exons—19b and
38—also failed to show a mutation in our study pop-
ulation, and other exons—such as 4a and 33—harbored
only a single mutation. The reason for this underrepre-
sentation in the compulsory exons is not clear and may
be purely accidental. For exons 33 and 38, additional
mutations have been reported to the consortium (Korf
1998).
In general, the mutational spectrum of the NF1 gene
seems to be very similar to that of other tumor-sup-
pressor and mutator genes, which all seem to be char-
acterized by a large proportion of truncating muta-
tions—for example, nearly 100% for APC (Suzuki et al.
1998) and TSC1 (Jones et al. 1999), 180% for RB1
(Lohmann et al. 1996; 1997), ∼80% for BRCA1 (Miki
et al. 1994) and ATM (Sandoval et al. 1999), and ∼60%
for TSC2 (Jones et al. 1999), and all six NBS1 gene
mutations identified to date (Varon et al. 1998). Simi-
larly, 5%–20% missense mutations, as well as whole-
gene deletions, have been found in some of these genes
(RB1, ATM, TSC2). In addition, the problem of unsuc-
cessful mutation detection in many of the patients is
common to all these genes. Little more than half of all
the NF1 alleles investigated in this study yielded a de-
tectable mutation. It is true that the PTT protocol used
here might have failed to detect missense as well as splic-
ing-error mutations—especially those that result in in-
frame skips of small exons— but, in most cases, all exons
and adjacent intron regions of the NF1 gene were se-
quenced. DGS, like TGGE, is commonly thought to pro-
vide a sensitivity close to 100% in the analyzed regions,
and, although some problems with heterozygote detec-
tion in automated sequencing are known to impair the
identification rate of point mutations, this alone is un-
likely to account for missing 140% of the NF1 muta-
tions. Some of the unidentified mutations are definitely
large deletions comprising the whole NF1 gene or a ma-
jor part of it. When analyzing 15 TGGE-negative cases
by fluorescence in situ hybridization, we identified three
NF1 gene deletions (G. Thiel, unpublished data). Hence,
we estimate the overall proportion of gross genomic de-
letions to be ∼10%. Among the remaining 35% of un-
detected mutations, multiexon deletions may represent
the largest group (15% of all mutations, according to
the consortium data [Korf 1998]). Furthermore, large
duplications or inversions would also have escaped our
PCR-based mutation scanning (Naylor et al. 1993). In-
complete assessment of intronic and regulatory se-
quences probably accounts for other unidentified cases.
However, NF1 promoter mutations seem to be rare and
the sequence variants identified so far are unlikely to
cause the disease phenotype (Osborn and Upadhyaya
1998). For the RB1 gene, silencing of the promoter by
allele-specific hypermethylation of a CpG island in the
5′ region was shown in 10% of retinoblastomas (Sakai
et al. 1991; Greger et al. 1994). Interestingly, a hypo-
methylated region near the transcription start site within
the NF1 CpG island could act as a target for silencing
of the NF1 gene by local hypermethylation (Rodenhiser
et al. 1998). Thus, epigenetic and genetic mechanisms
may cause inactivation of NF1 transcription. Recent
studies have shown that somatic mosaicism may be a
frequent finding among sporadic cases of NF1 (Colman
et al. 1996; Ainsworth et al. 1997; Tonsgard et al. 1997;
Wu et al. 1997; Rasmussen et al. 1998). Provided the
mutation was present in the tissues analyzed, the meth-
ods used for exon screening in this study are unlikely to
have had sufficient sensitivity to detect low-level mo-
saicism. Unfortunately, we cannot exclude the possibility
that patients who did not have NF1 were included in
the screening, because some of the patients were diag-
nosed by others. Finally, the existence of genetic heter-
ogeneity in NF1 is still an open discussion.
High Mutation Rate
The mutation rate for NF1 is one of the highest known
for human disorders, estimated to be between 1#104
and 3.1#105 (Sergeyev 1975; Huson et al. 1989; Cle-
menti et al. 1990). Thus, the NF1 gene seems to mutate
10 times more often than other disease genes. Several
reasons have been proposed to explain the high muta-
bility of the NF1 gene, including its relatively large size
of ∼350 kb, gene-conversion events via pseudogenes,
and mutational hotspots. Acting on the results of our
study, we can definitely exclude the many NF1 pseu-
dogenes as a major reason. Furthermore, pronounced
hotspots of mutation have not yet been identified in the
NF1 gene. It is true that some of the recurrentmutations,
such as R1513X and R1947X, affect CpG dinucleotides,
but the overall proportion of CrT or GrA transitions
within CpGs is as low as 19% of all mutations and 32%
of all the single-base-pair substitutions. Many other
genes show similar or even higher percentages of CpG
mutations—for example, 46% of factor VIII point mu-
tations in hemophilia A (Antonarakis et al. 1995),
45%–50% of TP53 point mutations in colorectal cancer
(Greenblatt et al. 1994), and 20%–25% of all RB1 mu-
tations (Cowell et al. 1994). Likewise, overlap between
pseudogene sequence variants and NF1 germline mu-
tations as identified in this study is negligible. Therefore,
we assume the large size of theNF1 gene to be the major
reason for the high mutation rate, which is in fact not
considerably higher than that of other large genes. In
Duchenne muscular dystrophy, which is caused by mu-
tations in an even larger gene (79 exons in 2.5 Mb), a
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similar high mutation rate is found (Vogel andMotulsky
1997). Interestingly, current estimates in Marfan syn-
drome place its prevalence at 1 per 3,000–5,000 people
(Pyeritz 1996). This suggests that the FBN1 gene (65
exons in 110 kb), which is very similar in size to the
NF1 gene, has a mutation rate nearly as high as in NF1.
Second Functional Domain
Our characterization of significant numbers of mis-
sense mutations and some small in-frame deletions is
likely to be helpful in the investigation of putative func-
tions of the NF1 gene product. The RasGAP activity of
the central GAP-related domain and the structure of the
GRD from neurofibromin have already been well char-
acterized (Kim and Tamanoi 1998; Scheffzek et al.
1998), in particular, the effects of mutations of the ar-
ginine finger (Arg 1276) were studied in detail (Ahma-
dian et al. 1997; Klose et al. 1998a). Clustering of mis-
sense mutations in the GRD, as observed in this and
other studies (fig. 5), is what we could expect from its
functional relevance. However, there is another segment
in the NF1 gene, upstream of the GRD, that harbors
numerous missense mutations as well (see fig. 5). We
assume this region defines a second functional domain
of the neurofibromin molecule. Interestingly, this region
coincides with the cysteine/serine-rich domain (CSRD)
defined by Izawa et al. (1996). The CSRD comprises
amino acid residues 543–909, in which three cysteine
pairs (residues 622/632, 673/680, and 714/721) may be
comparable to those that Maru et al. (1991) suggested
form the ATP-binding domain of BCR protein. Fur-
thermore, this sequence harbors three potential cAMP-
dependent protein kinase A (PKA) recognition sites
(Marchuk et al. 1991). These are, indeed, subject to
phosphorylation by PKA (Izawa et al. 1996), and one
is mutated in two of our NF1 families (mutation K583R
in exon 12a). A second is situated in a small region
(residues 815–834) of sequence similarity with two other
proteins (MAP-2 and tau) that also associate with mi-
crotubules. It has been speculated that phosphorylation
of this region might regulate the association of neuro-
fibromin and microtubules (Gregory et al. 1993). The
functional significance of the phosphorylation of neu-
rofibromin by PKA is still unclear, but in view of the
compelling evidence for the involvement of neurofi-
bromin in cAMP-mediated signaling from Drosophila
(Guo et al. 1997; The et al. 1997), it may explain the
observed link between the second messenger cAMP and
the Ras signaling pathway (Wu et al. 1993).
In summary, we have attributed functional relevance
to a new region of the neurofibromin molecule on the
basis of the missense mutations identified in a large co-
hort of NF1 patients. This protein segment was found
upstream of the GRD and may be identical with the
CSRD described elsewhere (Izawa et al. 1996). PKA
phosphorylation sites within the domain suggest this re-
gion might be involved in cAMP-mediated signaling.
However, further studies will be required to substantiate
our hypothesis. To this end, the functional significance
of the relevant missense mutations is currently being
tested in the Drosophila model.
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